Skip to content


Agrylin, Xagrid (anagrelide) is a small molecule pharmaceutical. Anagrelide was first approved as Agrylin on 1997-03-14. It is used to treat polycythemia vera and thrombocytosis in the USA. It has been approved in Europe to treat essential thrombocythemia. The pharmaceutical is active against cGMP-inhibited 3',5'-cyclic phosphodiesterase A.
Trade Name Xagrid
Common Name Anagrelide
Indication essential thrombocythemia, polycythemia vera, thrombocytosis
Drug Class Platelet aggregation inhibitors
Get full access now